ELIGARD 22.5mg

DRUG2 trials

Sponsors

HanAll BioPharma Co., Ltd., Ontario Clinical Oncology Group (OCOG)

Conditions

Castration Sensitive Prostate CancerProstate AdenocarcinomaProstate Cancer

Phase 2

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

RecruitingNCT06654336

Ontario Clinical Oncology Group (OCOG)Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma

Start: 2026-05-06End: 2031-06-01Target: 162Updated: 2026-08-31

Phase 4

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

CompletedNCT01511874

HanAll BioPharma Co., Ltd.Prostate Cancer

Start: 2011-01-31End: 2013-12-31Updated: 2015-09-23

Related Papers

OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).

Journal of Clinical Oncology2025-02-10